Cargando…

The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review

Metformin and sulphonylureas are the most commonly used first-line anti-diabetic agents. However, medical practice guidelines and clinical experience caution against using these drugs in severe diabetic kidney disease. Consequently, the choice of anti-diabetic medicine in various stages of diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Boddepalli, Chinmayi Sree, Gutlapalli, Sai Dheeraj, Lavu, Vamsi Krishna, Abdelwahab Mohamed Abdelwahab, Rana, Huang, Ruimin, Potla, Shanthi, Bhalla, Sushen, AlQabandi, Yousif, Nandula, Savitri Aninditha, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822529/
https://www.ncbi.nlm.nih.gov/pubmed/36628027
http://dx.doi.org/10.7759/cureus.32286
_version_ 1784865968403513344
author Boddepalli, Chinmayi Sree
Gutlapalli, Sai Dheeraj
Lavu, Vamsi Krishna
Abdelwahab Mohamed Abdelwahab, Rana
Huang, Ruimin
Potla, Shanthi
Bhalla, Sushen
AlQabandi, Yousif
Nandula, Savitri Aninditha
Khan, Safeera
author_facet Boddepalli, Chinmayi Sree
Gutlapalli, Sai Dheeraj
Lavu, Vamsi Krishna
Abdelwahab Mohamed Abdelwahab, Rana
Huang, Ruimin
Potla, Shanthi
Bhalla, Sushen
AlQabandi, Yousif
Nandula, Savitri Aninditha
Khan, Safeera
author_sort Boddepalli, Chinmayi Sree
collection PubMed
description Metformin and sulphonylureas are the most commonly used first-line anti-diabetic agents. However, medical practice guidelines and clinical experience caution against using these drugs in severe diabetic kidney disease. Consequently, the choice of anti-diabetic medicine in various stages of diabetic nephropathy should balance the benefits and risks to the patient. We aim to synthesize available evidence on the effectiveness and safety of metformin concerning sulfonylureas in patients with diabetic renal disease. The COSMOS-E (Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology) and MOOSE (Meta-Analyses and Systematic Reviews of Observational Studies in Epidemiology) guidelines were followed when designing the systematic review. The present study assessed the effectiveness of metformin and sulphonylurea monotherapy regarding renal function. Studies published from 2001 to 2022 were included. We have identified 570 records from PubMed, BioMed Central, LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde), ScienceDirect, and PLoS (The Public Library of Science) Medicine databases. Eight cohort studies met the inclusion criteria. All studies reported adjusted hazard ratios with confidence limits. Metformin was found to be more effective in the following events: all-cause mortality, GFR (glomerular filtration rate), ESRD (end-stage renal disease) or death events, one-year risk of death or end-stage renal disease, cardiovascular events, heart failure hospitalization, and hypoglycemic episodes. However, metformin was less effective in acute renal replacement therapy, end-stage renal disease, and/or death, with a one-year risk of acute dialysis. Lactic acidosis was not significant with metformin. The present study recommends that metformin therapy is safe compared to sulfonylurea therapy in diabetic nephropathy patients, provided that the contraindications given in the guidelines are strictly adhered to.
format Online
Article
Text
id pubmed-9822529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98225292023-01-09 The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review Boddepalli, Chinmayi Sree Gutlapalli, Sai Dheeraj Lavu, Vamsi Krishna Abdelwahab Mohamed Abdelwahab, Rana Huang, Ruimin Potla, Shanthi Bhalla, Sushen AlQabandi, Yousif Nandula, Savitri Aninditha Khan, Safeera Cureus Internal Medicine Metformin and sulphonylureas are the most commonly used first-line anti-diabetic agents. However, medical practice guidelines and clinical experience caution against using these drugs in severe diabetic kidney disease. Consequently, the choice of anti-diabetic medicine in various stages of diabetic nephropathy should balance the benefits and risks to the patient. We aim to synthesize available evidence on the effectiveness and safety of metformin concerning sulfonylureas in patients with diabetic renal disease. The COSMOS-E (Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology) and MOOSE (Meta-Analyses and Systematic Reviews of Observational Studies in Epidemiology) guidelines were followed when designing the systematic review. The present study assessed the effectiveness of metformin and sulphonylurea monotherapy regarding renal function. Studies published from 2001 to 2022 were included. We have identified 570 records from PubMed, BioMed Central, LILACS (Literatura Latino-Americana e do Caribe em Ciências da Saúde), ScienceDirect, and PLoS (The Public Library of Science) Medicine databases. Eight cohort studies met the inclusion criteria. All studies reported adjusted hazard ratios with confidence limits. Metformin was found to be more effective in the following events: all-cause mortality, GFR (glomerular filtration rate), ESRD (end-stage renal disease) or death events, one-year risk of death or end-stage renal disease, cardiovascular events, heart failure hospitalization, and hypoglycemic episodes. However, metformin was less effective in acute renal replacement therapy, end-stage renal disease, and/or death, with a one-year risk of acute dialysis. Lactic acidosis was not significant with metformin. The present study recommends that metformin therapy is safe compared to sulfonylurea therapy in diabetic nephropathy patients, provided that the contraindications given in the guidelines are strictly adhered to. Cureus 2022-12-07 /pmc/articles/PMC9822529/ /pubmed/36628027 http://dx.doi.org/10.7759/cureus.32286 Text en Copyright © 2022, Boddepalli et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Boddepalli, Chinmayi Sree
Gutlapalli, Sai Dheeraj
Lavu, Vamsi Krishna
Abdelwahab Mohamed Abdelwahab, Rana
Huang, Ruimin
Potla, Shanthi
Bhalla, Sushen
AlQabandi, Yousif
Nandula, Savitri Aninditha
Khan, Safeera
The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title_full The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title_fullStr The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title_full_unstemmed The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title_short The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
title_sort effectiveness and safety of metformin compared to sulfonylureas in diabetic nephropathy: a systematic review
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822529/
https://www.ncbi.nlm.nih.gov/pubmed/36628027
http://dx.doi.org/10.7759/cureus.32286
work_keys_str_mv AT boddepallichinmayisree theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT gutlapallisaidheeraj theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT lavuvamsikrishna theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT abdelwahabmohamedabdelwahabrana theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT huangruimin theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT potlashanthi theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT bhallasushen theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT alqabandiyousif theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT nandulasavitrianinditha theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT khansafeera theeffectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT boddepallichinmayisree effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT gutlapallisaidheeraj effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT lavuvamsikrishna effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT abdelwahabmohamedabdelwahabrana effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT huangruimin effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT potlashanthi effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT bhallasushen effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT alqabandiyousif effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT nandulasavitrianinditha effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview
AT khansafeera effectivenessandsafetyofmetformincomparedtosulfonylureasindiabeticnephropathyasystematicreview